A Live Recombinant Newcastle Disease Virus-vectored COVID-19 Vaccine Phase 1 Study.

• ClinicalTrials.gov Identifier: NCT05181709
• Recruitment Status: Active, not recruiting
• First Posted: January 6, 2022
• Last Update Posted: April 26, 2024
• Sponsor: Sean Liu
• Information provided by (Responsible Party): Sean Liu, Icahn School of Medicine at Mount Sinai

Study Description

Brief Summary:

This study will be a phase-1, open-label, placebo-controlled, evaluation of two-dosages of a live, recombinant Newcastle disease virus expressing the spike protein of SARS-CoV-2 (NDV-HXP-S), an investigational product for IN, IM, or a combined IN+IM vaccination in healthy adults previously immunized against COVID-19. The IN and IM live virus vaccinations will be identical in composition and only differ in route of administration.

Condition or disease	Intervention/treatment	Phase
SARS-CoV-2	Drug: Sodium Chloride; Biological: NDV-HXP-S IN low dose; Biological: NDV-HXP-S IM low dose; Biological: NDV-HXP-S IN high dose; Biological: NDV-HXP-S IM high dose	Phase 1

Detailed Description:

Primary Study Objective: To evaluate the safety and tolerability profile of two dose levels of the NDV-HXP-S vaccine as an IN, IM, or a combined administration IN+IM to healthy, previously immunized adults up to 14 days after administration.

Secondary Study Objective: To evaluate the safety and tolerability profile of two dose levels of the NDV-HXP-S vaccine as an IN, IM, or a combined administration IN+IM to healthy, previously immunized adults up to 365 days after administration.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 35 participants
• Allocation: Randomized
• Intervention Model: Sequential Assignment
• Intervention Model Description: Random and Sequential Assignment
• Masking: None (Open Label)
• Primary Purpose: Prevention
• Official Title: A Phase-1, Open-Label, Placebo-Controlled Evaluation of a Live, Recombinant Newcastle Disease Virus Expressing the Spike Protein of SARS-CoV-2 (NDV-HXP-S), an Investigational Product for Intranasal (IN) and/or Intramuscular (IM) Vaccination in Healthy Adults Previously Immunized Against COVID-19.
• Actual Study Start Date: February 9, 2022
• Actual Primary Completion Date: May 3, 2023
• Estimated Study Completion Date: April 2024

Arms and Interventions

Arm	Intervention/treatment
Placebo Comparator: Cohort 1: Placebo / Sodium Chloride; Participants in Cohort 1 will receive placebo given IN+IM in combination. Placebo administration will be given in an ambulatory setting. IN administration will be immediately followed by IM administration. Participants will be monitored by the research staff for 1-hour after administration. Participants will be permitted to receive any additional federally authorized or approved vaccines 56 days after receiving placebo.	Drug: Sodium Chloride; Administered intranasal (IN) and intramuscular (IM) in combination; Other Name: Placebo
Active Comparator: Cohort 2: NDV-HXP-S low dose IN; Participants in Cohort 2 (low, IN) will receive a single administration of a low dose of NDV-HXP-S at 3.3x108 Egg-Infectious Dose50 (EID50). Participants will be given NDV-HXP-S in an ambulatory setting and be monitored by the research staff for 4 hours post-administration. Participants will then return home under home isolation. Home isolation will require daily at-home sample collections and online symptom reporting. Discontinuation of home isolation will require laboratory confirmation of negative NDV-HXP-S virus detection.	Biological: NDV-HXP-S IN low dose; Allantoic fluid diluted in Phosphate buffered saline (PBS), to be further diluted to dose strength in sodium chloride. Strength: 3.3x108^8 EID50.
Active Comparator: Cohort 3: NDV-HXP-S low dose IM; Participants in Cohort 3 (low, IM) will receive a single administration of a low dose of NDV-HXP-S at 3.3x108 Egg-Infectious Dose50 (EID50). Participants will be given NDV-HXP-S in an ambulatory setting and be monitored by the research staff for 4 hours post-administration. Participants will then return home under home isolation. Home isolation will require daily at-home sample collections and online symptom reporting. Discontinuation of home isolation will require laboratory confirmation of negative NDV-HXP-S virus detection.	Biological: NDV-HXP-S IM low dose; Allantoic fluid diluted in Phosphate buffered saline (PBS), to be further diluted to dose strength in sodium chloride. Strength: 3.3x10^8 EID50.
Active Comparator: Cohort 4: NDV-HXP-S low dose IN+IM in combination; Participants in Cohort 4 (low, IN+IM) will receive low doses of NDV-HXP-S at 3.3x108 EID50. Participants will be given NDV-HXP-S in an ambulatory setting where IN and IM doses will be given in succession. Participants will be monitored by the research staff for 4 hours post-administration. Participants will then return home under home isolation. Home isolation will require daily at-home sample collections and online symptom reporting. Discontinuation of home isolation will require laboratory confirmation of negative NDV-HXP-S virus detection.	Biological: NDV-HXP-S IN low dose; Allantoic fluid diluted in Phosphate buffered saline (PBS), to be further diluted to dose strength in sodium chloride. Strength: 3.3x108^8 EID50.; Biological: NDV-HXP-S IM low dose; Allantoic fluid diluted in Phosphate buffered saline (PBS), to be further diluted to dose strength in sodium chloride. Strength: 3.3x10^8 EID50.
Active Comparator: Cohort 5: NDV-HXP-S high dose IN; Participants in Cohort 5 (high, IN) will receive high doses of NDV-HXP-S at 1x109 EID50. Participants will ONLY enroll into Cohort 5 if Cohort 2 (low dose IN) did not have any SAEs that required additional participants. Participants will be given NDV-HXP-S in an ambulatory setting and be monitored by the research staff for 4 hours post-administration. Participants will then return home under home isolation. Home isolation will require daily at-home sample collections and online symptom reporting. Discontinuation of home isolation will require laboratory confirmation of negative NDV-HXP-S virus detection.	Biological: NDV-HXP-S IN high dose; Allantoic fluid diluted in Phosphate buffered saline (PBS). Strength: 1x10^9 EID50.
Active Comparator: Cohort 6: NDV-HXP-S high dose IM; Participants in Cohort 6 (high, IM) will receive high doses of NDV-HXP-S at 1x109 EID50. Participants will ONLY enroll into Cohort 6 if Cohort 3 (low dose IM) did not have any SAEs that required additional participants. Participants will be given NDV-HXP-S in an ambulatory setting and be monitored by the research staff for 4 hours post-administration. Participants will then return home under home isolation. Home isolation will require daily at-home sample collections and online symptom reporting. Discontinuation of home isolation will require laboratory confirmation of negative NDV-HXP-S virus detection.	Biological: NDV-HXP-S IM high dose; Allantoic fluid diluted in Phosphate buffered saline (PBS). Strength: 1x10^9 EID50.
Active Comparator: Cohort 7: NDV-HXP-S high dose IN+IM in combination; Participants in Cohort 7 (high, IN+IM) will receive high doses of NDV-HXP-S at 1x109 EID50. Participants will only enroll into Cohort 7 if Cohort 4 did not have an SAE that required additional participants. Participants will be given NDV-HXP-S in an ambulatory setting and be monitored by the research staff for 4 hours post-administration. Participants will then return home under home isolation. Home isolation will require daily at-home sample collection and online symptom reporting. Discontinuation of home isolation will require laboratory confirmation of negative NDV-HXP-S virus detection.	Biological: NDV-HXP-S IN high dose; Allantoic fluid diluted in Phosphate buffered saline (PBS). Strength: 1x10^9 EID50.; Biological: NDV-HXP-S IM high dose; Allantoic fluid diluted in Phosphate buffered saline (PBS). Strength: 1x10^9 EID50.

Outcome Measures

Primary Outcome Measures :

1. Number of local and systemic reactions [ Time Frame: 14 days ]
   The safety and tolerability profile assessed by the number of local and systemic reactions.

Secondary Outcome Measures :

1. Number of adverse events (AEs) [ Time Frame: 365 days ]
   The safety and tolerability profile assessed by the number of serious adverse events.
2. Number of serious adverse events (SAEs) [ Time Frame: 365 days ]
   The safety and tolerability profile assessed by the number of serious adverse events.
3. Number of medically-attended adverse events (MAAEs) [ Time Frame: 365 days ]
   The safety and tolerability profile assessed by the number of medically-attended adverse events (MAAEs).

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 59 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

1. Willing and able to provide written informed consent prior to performing study procedures.
2. Males and non-pregnant females who are between 18 to 59 years of age.
3. Asymptomatic, RT-PCR negative (at screening) AND without a known prior history of COVID-19 infection (requiring a negative SARS-CoV-2 nucleocapsid antibody test result at screening).
4. Provides documentation showing completion of an FDA authorized or approved COVID-19 vaccination regimen, where the last administration was ≥ 6 months (180 days) from the study enrollment date.

5. IF FEMALE PARTICIPANT: A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:

   • Is not a woman of child-bearing potential (WOCBP); OR
   • Is a WOCBP and using an acceptable contraceptive method during the intervention period (for a minimum of 90 days after NDV-HXP-S vaccination). The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention. Only highly effective methods of contraception that have a low user dependency or a combination of highly effective methods that are user dependent may be used.

6. IF MALE PARTICIPANT: Agrees to the following requirements during the intervention period and for at least 90 days after NDV-HXP-S vaccination, which corresponds to the time needed to eliminate reproductive safety risk of the study intervention(s):

   • Refrain from donating sperm AND be abstinent from heterosexual intercourse with a female of childbearing potential as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent; OR
   • Must agree to use a male condom when engaging in any activity that allows for passage of ejaculate to another person. In addition to male condom use, a highly effective method of contraception may be considered in WOCBP partners of male participants.
7. Participant understands and agrees to comply with planned study procedures.
8. Participant agrees to not participate in another clinical trial for treatment of COVID-19 or SARS-CoV-2 through Day 365.
9. Participant agrees to not receive any other vaccination (including COVID-19 vaccines) through day 56 of the study.
10. Provides consent for release of information for hospitalization records and other medically attended visits during the study.

Exclusion Criteria:

1. Clinical and/or laboratory evidence indicative of COVID-19 infection.
2. Demonstrates a STRONG COVID-19 positive antibody serology (>12500 AU/ml per chemiluminescent microparticle immunoassay (including AdviseDx SARS-CoV-2 IgG II)) or a NEGATIVE COVID-19 serology on screening against SARS-CoV-2 spike protein.
3. History of hypersensitivity to egg products.
4. History of severe reactions to vaccinations.
5. Potential for prior NDV exposures (i.e., experience as a bird-handler, poultry farmer, or scientist conducting research with NDV).
6. History of an immunocompromising medical condition (such as primary immunodeficiencies, AIDS, or neutropenia).
7. Current or recent use of immunosuppressive medications (i.e., any systemic corticosteroids, chemotherapeutics, immunoglobulin therapies, etc.) based on the assessment of their half-life by the investigator.
8. Any history of HIV, hepatitis C, hepatitis B (by laboratory testing and/or history), Guillain-Barré syndrome, and/or recent receipt of immunoglobulins and/or blood products.
9. Pregnancy or actively breastfeeding.
10. Other medical condition or abnormal laboratory values which may place participant at increased risk for harm due to participation in the study as determined by the investigator.
11. In the opinion of the investigator that it would be unwise to allow the participant to be randomized into the study, including those persons who the investigator would consider as high risk of SARS-CoV-2 exposure, including healthcare workers with direct patient care and laboratory workers who handle SARS-CoV-2.
12. Participants at higher risk of severe COVID-19, as defined by CDC guidance (https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/index.html), where severity of risk and eligibility will be determined by the investigator. This guidance includes details regarding older adults, people with specific medical conditions, and pregnant and recently pregnant people.
13. Participants with fever or signs of acute infection, including symptoms that could indicate SARS-CoV-2 infection.
14. Participants with a history of chronic rhinitis, nasal septal defect, cleft palate, nasal polyps, or other nasal abnormality that might affect vaccine administration.
15. Participants who prepare food in the food industry and childcare workers who have direct contact with children 5 years of age or younger.

16. Participants who have close or household high-risk contacts including but not limited to:

    • Persons more than or equal to 65 years of age
    • Children less than or equal to 5 years of age.
    • Residents of nursing homes.
    • Persons of any age with significant chronic medical conditions as well as immunosuppression or cancer.

    Women who are pregnant, trying to become pregnant, or breastfeeding.

17. Participants who are students, post-doctoral candidates, or trainees of the study site, or are members of the research staff.
18. Participants with a history of myocarditis or pericarditis and individuals with an abnormal troponin or abnormal ECG as determined by the investigator. Participants with a screening 12-lead ECG that shows an average QTc interval >500 msec, complete left bundle branch block, ST-T interval changes suggestive of myocardial ischemia, second- or third-degree AV block, or serious bradyarrhythmias or tachyarrhythmias should be excluded from study participation.

Contacts and Locations

Locations

United States, New York

Icahn School of Medicine at Mount Sinai

New York, New York, United States, 10029

Sponsors and Collaborators

Sean Liu

Investigators

• Principal Investigator: Sean Liu, MD, PhD; Icahn School of Medicine at Mount Sinai

More Information

Additional Information:

Mount Sinai Develops a Safe, Low-Cost COVID-19 Vaccine That Could Help Low- and Middle-Income Countries 

Publications:

Sun W, McCroskery S, Liu WC, Leist SR, Liu Y, Albrecht RA, Slamanig S, Oliva J, Amanat F, Schafer A, Dinnon KH 3rd, Innis BL, Garcia-Sastre A, Krammer F, Baric RS, Palese P. A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine. Vaccines (Basel). 2020 Dec 17;8(4):771. doi: 10.3390/vaccines8040771.

Punnee Pitisuttithum, Viravarn Luvira, Saranath Lawpoolsri, Sant Muangnoicharoen, Supitcha Kamolratanakul, Chaisith Sivakorn, Piengthong Narakorn, Somchaiya Surichan, Sumalee Prangpratanporn, Suttida Puksuriwong, Steven Lamola, Laina D Mercer, Rama Raghunandan, Weina Sun, Yonghong Liu, Juan Manuel Carreño, Rami Scharf, Weerapong Phumratanaprapin, Fatima Amanat, Luc Gagnon, Ching-Lin Hsieh, Ruangchai Kaweepornpoj, Sarwat Khan, Manjari Lal, Stephen McCroskery, Jason McLellan, Ignacio Mena, Marcia Meseck, Benjaluck Phonrat, Yupa Sabmee, Ratsamikorn Singchareon, Stefan Slamanig, Nava Suthepakul, Johnstone Tcheou, Narumon Thantamnu, Sompone Theerasurakarn, Steven Tran, Thanakrit Vilasmongkolchai, Jessica A White, Adolfo Garcia-Sastre, Peter Palese, Florian Krammer, Kittisak Poopipatpol, Ponthip Wirachwong, Richard Hjorth, Bruce L Innis. Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial. medRxiv 2021.09.17.21263758; doi: https://doi.org/10.1101/2021.09.17.21263758

• Responsible Party: Sean Liu, Assistant Professor, Icahn School of Medicine at Mount Sinai
• ClinicalTrials.gov Identifier: NCT05181709
• Other Study ID Numbers: STUDY-21-01589
• First Posted: January 6, 2022
• Last Update Posted: April 26, 2024
• Last Verified: April 2024

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes
• Plan Description: All of the individual participant data collected during the trial, after de-identification.
• Supporting Materials: Study Protocol; Statistical Analysis Plan (SAP)
• Time Frame: Immediately following publication. No end date.
• Access Criteria: Investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose. To achieve aims in the approved proposal.

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

Keywords provided by Sean Liu, Icahn School of Medicine at Mount Sinai:

SARS-CoV-2; COVID-19; Vaccine; Booster

Additional relevant MeSH terms:

COVID-19; Newcastle Disease; Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases; Avulavirus Infections; Paramyxoviridae Infections; Mononegavirales Infections